Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
08:45am, Friday, 19'th Sep 2025
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Why Shares in Novo Nordisk Soared This Week
07:22am, Friday, 19'th Sep 2025
Novo Nordisk (NVO 6.36%) shares surged by 12.7% in the week to Friday morning as investors received positive news on an orally administered weight loss drug pivotal to the company's future.
Wall Street Breakfast Podcast: FedEx Delivers Earnings Surprise
06:29am, Friday, 19'th Sep 2025
FedEx (FDX) surges after beating FQ1 earnings expectations, reporting revenue growth, and advancing its FedEx Freight spin-off, targeted for June 2026. Cracker Barrel (CBRL) faces renewed activist pre
Novo Nordisk: Attractive Buying Opportunity In A Distracted Market
11:52pm, Thursday, 18'th Sep 2025
Novo Nordisk's recent stock decline looks like a market overreaction to a lot of noise, presenting a strong long-term buying opportunity at a discounted price. The new CEO's restructuring could improv
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffe
Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join – Contact The Gross Law Firm
04:41pm, Thursday, 18'th Sep 2025
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
GOOGL, NVO, Small Caps & Other Value Plays in All-Time High Market
03:30pm, Thursday, 18'th Sep 2025
Jeff McClean says A.I. valuations have ballooned to the point where the value in many have been lost.
Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts
03:25pm, Thursday, 18'th Sep 2025
Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reu
Novo Nordisk shares surge after Wegovy pill trial shows ‘significant' weight reduction
02:14pm, Thursday, 18'th Sep 2025
CNBC's Angelica Peebles reports on Novo Nordisk shares surging after the company announced that its Wegovy pill trial showed ‘significant' weight reduction.
Why Novo Nordisk Stock Popped Again Today
01:31pm, Thursday, 18'th Sep 2025
Novo Nordisk (NVO 6.19%) -- the original Ozempic stock -- jumped higher again Thursday after announcing results from a weight loss study that had patients taking its Wegovy GLP-1 weight loss drug oral
BENSALEM, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today
12:05pm, Thursday, 18'th Sep 2025
Two of the hottest healthcare stocks in recent years have been Novo Nordisk (NVO 6.10%) and Eli Lilly (LLY 0.46%). The former has risen by 400% in the past five years, while the latter is up 67%.
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
11:51am, Thursday, 18'th Sep 2025
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
Novo Nordisk shares climb after positive results for anti-obesity pill
11:33am, Thursday, 18'th Sep 2025
Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss' with tablet version of Wegovy
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
11:14am, Thursday, 18'th Sep 2025
Novo Nordisk A/S NVO looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is startin
